Navigation Links
Dragon Pharma announces date of special meeting
Date:6/28/2010

VANCOUVER, June 28 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: DRUG) announced that its Special Meeting of Shareholders will be held on Tuesday, July 20, 2010 at 10:30 a.m., Pacific Time at the Company's corporate office located at Suite 310, 650 West Georgia Street, Vancouver, British Columbia, Canada V6B 4N9. Only shareholders of record of as of May 28, 2010 will be entitled to vote upon the proposed Agreement and Plan of Merger by and among Dragon, Chief Respect Limited, a Hong Kong corporation, Datong Investment Inc., a Florida corporation and subsidiary of Chief Respect Limited, and Mr. Yanlin Han, pursuant to which Datong Investment Inc. will merge with and into Dragon and each holder of Dragon shares of common stock, excluding Mr. Han, will receive $0.82 per share. Notice of the meeting and accompany proxy statement are being mailed to shareholders on June 28, 2010.

Additional Information and Where to Find It

In connection with the proposed merger, the Company has filed with the Securities and Exchange Commission (the "SEC") a Schedule 13E-3, and a definitive proxy statement for the meeting of stockholders of the Company to be convened to approve the merger. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, DRAGON'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Stockholders may obtain a free copy of the proxy statement, and other documents filed by us with the SEC, at the SEC's web site at http://www.sec.gov. Free copies of the proxy statement and our other filings with the SEC may also be obtained from us. Free copies of our filings may be obtained by directing a request to Dragon Pharmaceutical, Inc., 650 West Georgia Street, Suite 310, Vancouver, British Columbia, Canada V6B 4N9 Attention: Maggie Deng, Secretary. Copies of the proxy statement may also be obtained at our website, www.dragonpharma.com.

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including Clavulanic Acid, an API to combine with Amoxicillin to fight resistance, and 7-ACA, a key intermediate to produce cephalosporin antibiotics, and formulated cephalosporin antibiotic drugs. To learn more about Dragon Pharmaceutical Inc., please visit www.dragonpharma.com.


'/>"/>
SOURCE Dragon Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dragon Pharma reports 2010 first quarter financial results
2. Dragon Pharma Announces Results of 2009 Annual General Meeting
3. Dragon Pharma Announces June 21, 2009 for 2009 Annual Shareholders Meeting
4. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
5. Dragon to Present at BioContact Quebec 2008
6. Dragon Pharma Announces Results of the Annual General Meeting
7. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
8. 3SBio Inc. to Present at The Oppenheimer 2nd Annual China Dragon Call Conference
9. Dragon Pharma announces 2007 full year financial results
10. Dragon retains leading investor relations firm
11. Dragon announces new product launch; increase in annual production output capacity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 24, 2017  Frost & Sullivan is pleased to announce that ... receive special recognition at the 22nd Annual Medical Technologies: A ... 21, 2017 at the Loews Coronado Bay Resort in ... download the event agenda for Medical Technologies 2017: A Frost & ... ...
(Date:1/24/2017)... BILLERICA, Mass. , Jan. 24, 2017 ... acquired Hysitron, Inc., a technology leader in ... test instrumentation. The acquisition adds Hysitron,s innovative ... of atomic force microscopes (AFMs), surface profilometers, ... enhancing Bruker,s leadership position in nanomaterials research ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... circumference, and increased serum leptin levels had a positive association with increased prostate ... study published in the International Neurourology Journal involved 571 Korean men who ...
(Date:1/24/2017)... , Jan. 24, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. ... today that its orally active lead drug candidate, PBI-4050, ... by the UK Medicines and Healthcare Products Regulatory Agency ... A PIM designation is an early indication ... the Early Access to Medicines Scheme ("EAMS"), intended for ...
Breaking Biology Technology:
(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
Breaking Biology News(10 mins):